birabresib

Ligand id: 8359

Name: birabresib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 120.64
Molecular weight 491.12
XLogP 5.16
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

References
1. Berenguer-Daizé C, Astorgues-Xerri L, Odore E, Cayol M, Cvitkovic E, Noel K, Bekradda M, MacKenzie S, Rezai K, Lokiec F et al.. (2016)
OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Int. J. Cancer139 (9): 2047-55. [PMID:27388964]
2. Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, Taussig DC, Rezai K, Roumier C, Herait P et al.. (2016)
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
Lancet Haematol3 (4): e186-95. [PMID:27063977]
3. Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, Rinaldi A, Testoni M, Cascione L, Ponzoni M et al.. (2015)
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
Clin. Cancer Res.21 (7): 1628-38. [PMID:25623213]
4. Boi M, Todaro M, Vurchio V, Yang SN, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M et al.. (2016)
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
Oncotarget7 (48): 79637-79653. [PMID:27793034]
5. Filippakopoulos P, Knapp S. (2014)
Targeting bromodomains: epigenetic readers of lysine acetylation.
Nat Rev Drug Discov13 (5): 337-56. [PMID:24751816]
6. Gaudio E, Tarantelli C, Ponzoni M, Odore E, Rezai K, Bernasconi E, Cascione L, Rinaldi A, Stathis A, Riveiro E et al.. (2016)
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Oncotarget7 (36): 58142-58147. [PMID:27494885]
7. Hattori N, Ushijima T. (2014)
Compendium of aberrant DNA methylation and histone modifications in cancer.
Biochem. Biophys. Res. Commun.455 (1-2): 3-9. [PMID:25194808]
8. Noel JK, Iwata K, Ooike S, Sugahara K, Nakamura H and Daibata M. 
Abstract C244: Development of the BET bromodomain inhibitor OTX015.
Accessed on 07/05/2015. Modified on 07/05/2015. aacrjournals.org, http://mct.aacrjournals.org/content/12/11_Supplement/C244.short
9. Odore E, Lokiec F, Cvitkovic E, Bekradda M, Herait P, Bourdel F, Kahatt C, Raffoux E, Stathis A, Thieblemont C et al.. (2016)
Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.
Clin Pharmacokinet55 (3): 397-405. [PMID:26341814]
10. Riveiro ME, Astorgues-Xerri L, Vazquez R, Frapolli R, Kwee I, Rinaldi A, Odore E, Rezai K, Bekradda M, Inghirami G et al.. (2016)
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.
Oncotarget7 (51): 84675-84687. [PMID:27835869]
11. Rosner M, Hengstschläger M. (2012)
Targeting epigenetic readers in cancer.
N. Engl. J. Med.367 (18): 1764-5. [PMID:23113498]
12. Vázquez R, Licandro SA, Astorgues-Xerri L, Lettera E, Panini N, Romano M, Erba E, Ubezio P, Bello E, Libener R et al.. (2017)
Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
Int. J. Cancer140 (1): 197-207. [PMID:27594045]
13. Vázquez R, Riveiro ME, Astorgues-Xerri L, Odore E, Rezai K, Erba E, Panini N, Rinaldi A, Kwee I, Beltrame L et al.. (2016)
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Oncotarget,  [Epub ahead of print]. [PMID:27935867]